InVivo Therapeutics (NVIV) Announces Promotions And New Organizational Roles To Further Drive Market Development And Awareness Of Spinal Cord Injury Innovation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced promotions for two members of its management team.

Christopher McNulty has been appointed as Senior Vice President, Business Development and Investor Relations. He will continue to lead all business development and corporate communications efforts, including investor relations and public relations. This role is a promotion from his previous role as Vice President, Business Development and Investor Relations. Before coming to InVivo in November 2013, Mr. McNulty served as Senior Director of Business Development at Repligen Corporation. Previously, he was Director of Corporate Development at Seventh Sense Biosystems, and Associate Director of Business Development and Alliance Management at Genzyme Corporation. He has an M.B.A. from Harvard Business School and B.S. and M.Eng. degrees from MIT.

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.